Akoya Biosciences和Shanghai KR Pharmtech宣布中国监管机构批准KR-HT5在中国上市，以支持下一代病理学临床工作流程-动脉橙

Akoya Biosciences和Shanghai KR Pharmtech宣布中国监管机构批准KR-HT5在中国上市，以支持下一代病理学临床工作流程

2024-05-02 GlobeNewswire 等3家媒体报道产品获批





Akoya Biosciences和上海KR Pharmtech联合宣布，他们共同开发的产品KR-HT5已获得中国NMPA的上市前批准。KR-HT5基于Akoya的PhenoImager HT技术，旨在支持中国的下一代病理学临床工作流程。该产品结合了Akoya的多光谱成像和光谱分解技术，为多重生物标志物分析提供了高通量平台。上海KR Pharmtech将KR-HT5整合到其下一代病理学解决方案中。两家公司都对此次合作和倡议的启动充满热情。（摘要由动脉网AI生成）

关联公司

 Akoya Biosciences

2024-05-02 Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

GlobeNewswire
2024-05-02 Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsKR-HT5 is based on Akoya’s PhenoImager® HT Platform

BioSpace
2024-05-03 Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

PHARMA FOCUS ASIA